August 2019 Cancer Epidemiology Matters E-News

Cancer Epidemiology Matters E-News

August 2019

NCI Program Directors: Who Are They and How Can They Help You?

What Is the Role of an NCI Program Director?

NCI program directors (PDs) provide scientific and administrative stewardship of research grants
and serve as points of contact for applicants pre- and post-review. Their duties include:

  • Managing a portfolio of grants within a particular scientific area;
  • Overseeing programmatic, scientific, and technical aspects of grants;
  • Identifying scientific opportunities, gaps in the institute’s research portfolio, and future research directions to address gaps;
  • Serving as a scientific liaison with other NIH institutes, government agencies, and professional societies; and
  • Fostering excellent science through interactions with investigators.

EGRP’s Program Directors

NCI’s Epidemiology and Genomics Research Program (EGRP) is currently served by more than 20 program directors with training and expertise in a variety of scientific areas, including, but not limited to, clinical and translational epidemiology; environmental epidemiology; genomic epidemiology; the development and validation of laboratory and technical approaches for large human population studies; and methods, tools, and technologies for risk factor assessment.

Submitting a Grant? Here’s When You Should Contact an EGRP Program Director

  • Early, before submission;
  • If you are seeking information about a policy/guideline;
  • If you are inquiring about a scientific area and funding opportunities for that area;
  • If you are inquiring about new scientific directions for an institute/program; or
  • If you have questions about a cancer epidemiology-related funding opportunity announcement (FOA).

During this stage in the application process, program directors can discuss how your research may fit with the NCI strategic priorities, clarify FOA or Notice of Special Interest (NOSI) intent, explain NIH pre-submission policies and procedures, process requests from investigators to submit large budget cancer epidemiology grant applications to NCI, coordinate/conduct pre-application meetings between NCI and principal investigators for complex applications, and offer general information about current peer review standards as well as appropriate funding mechanisms.

After your grant is reviewed, you may want to talk to a PD about the outcome of the review. Keep in mind that a PD cannot speak with you about the review until after the summary statement is available. The summary statement is usually available 4-6 weeks after the study section meeting is completed.

See also: Information for Early Stage and New Investigators, Sample Cancer Epidemiology Grant Applications.

Received Funding? Contact Your EGRP Program Director to Discuss…

  • Changes in the scope of your project, key personnel, grantee institution, or resource/data sharing plan;
  • Adding, removing, or transferring a foreign sub-award or foreign site;
  • Carrying over unobligated funds to the next year;
  • Significant re-budgeting of funds;
  • Requesting a second no-cost extension;
  • The annual progress report;
  • Grant closeout; or
  • Using other resources to enhance research (i.e., diet assessment resources, useful databases for sources of biologic specimens, genetic sequence and gene expression data, and more). See also: Resources & Opportunities for New Grantees.

Remember – EGRP PDs are here to help! Those who do not already have an assigned PD are invited to review the EGRP staff list to identify PDs with related scientific responsibilities. If you do not know who to contact in EGRP with specific questions or information requests, please e-mail

Funding Opportunities

  • Participant Engagement and Cancer Genome Sequencing (PE-CGS) (U2C -Clinical Trial Optional)
  • Participant Engagement and Cancer Genome Sequencing (PE-CGS) (U24 - Clinical Trial Not Allowed)
  • Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 - Clinical Trial Optional)

Return to Top